Earning Analysis
Welcome to our in-depth analysis of (AFMD) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: EUR
Actual
Estimate
Surprise Analysis
| FY2024Q2 | 2024-09-05 | Pre-Market | -1.00 | -1.09 | -9.00 | 1.15M | 154.00K | -86.65 | +1.07 | +2.67 |
| FY2024Q1 | 2024-06-12 | - | -1.73 | -1.38 | +20.23 | 962.94K | 155.00K | -83.90 | +5.05 | -7.35 |
| FY2023Q3 | 2023-11-14 | - | -0.21 | -0.17 | +19.05 | 1.89M | 1.96M | +3.98 | -3.05 | +44.82 |
| - | 2023-05-23 | - | -0.22 | -0.23 | -4.55 | - | - | - | -9.72 | -19.91 |
| - | 2023-03-23 | - | -0.19 | -0.22 | -15.79 | - | - | - | -6.40 | +1.07 |
| - | 2022-11-15 | - | -0.19 | -0.11 | +42.11 | - | - | - | +11.27 | +5.88 |
| - | 2022-08-11 | - | -0.18 | -0.14 | +22.22 | - | - | - | -9.06 | -4.53 |
| - | 2022-06-01 | - | -0.18 | -0.16 | +11.11 | - | - | - | +0.97 | -4.52 |
| - | 2022-03-31 | - | -0.17 | -0.22 | -29.41 | - | - | - | +2.10 | +9.35 |
| - | 2021-11-10 | - | -0.13 | -0.17 | -30.77 | - | - | - | -9.31 | -1.77 |
AFMD Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, reported performance for FY2024Q2, announced on 2024-09-05. The company achieved an EPS of -1.09, compared to analyst estimates of -1.00 by -9.00% . Revenue for the quarter reached 154.00K compared to expectations of 1.15M by -86.65% .
The stock price reacted with a 1.07% one-day change and a 2.67% five-day change following the earnings release. These movements reflect market reaction in growth trajectory and strategic initiatives.
AFMD Earnings Forecast
Looking ahead, (AFMD) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2024/Q4 project quarter revenue of 118.33K and an EPS of -0.87.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2024 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming Q4 2024, revenue estimates have been adjusted No Change by 0% . These revisions correlate with a 35.45% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between AFMD's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2024
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2024
No Change
0.00%
In Past 3 Month
Revenue Estimates for Q4 2024
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+35.45%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2024
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2024:779.75K
--
EPS Estimate-Annual FY 2024:-4.07
—
Stock Price0.18
AFMD Revenue and EPS Performance: A Historical Perspective
revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q2 (2024-09-05,Pre-Market):
EPS: -1.09 (Actual) vs.-1.00 (Estimate) (-9.00%)
Revenue: 154.00K (Actual) vs. 1.15M (Estimate) (-86.65%)
Price Reaction: 1.07%(1-Day), 2.67%(5-Day)
FY2024Q1 (2024-06-12,):
EPS: -1.38 (Actual) vs.-1.73 (Estimate) (20.23%)
Revenue: 155.00K (Actual) vs. 962.94K (Estimate) (-83.90%)
Price Reaction: 5.05%(1-Day), -7.35%(5-Day)
FY2023Q3 (2023-11-14,):
EPS: -0.17 (Actual) vs.-0.21 (Estimate) (19.05%)
Revenue: 1.96M (Actual) vs. 1.89M (Estimate) (3.98%)
Price Reaction: -3.05%(1-Day), 44.82%(5-Day)
Earnings Reaction
The chart below shows how AFMD performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AFMD sees a +1.51% change in stock price 10 days leading up to the earnings, and a +1.98% change 10 days following the report. On the earnings day itself, the stock moves by -1.71%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in JUN/2024, the stock changed -0.79% on the day following the earnings release and then changed by 4.49% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Affimed N.V. (AFMD) Q3 2024 Earnings Call Summary
Negative
2024-11-14
The earnings call summary shows a decrease in revenue and cash position, despite reduced expenses and net loss. The Q&A section highlights uncertainties regarding AFM28's FDA path, collaboration strategies, and data maturity. These factors, combined with unclear management responses, suggest investor concerns. The lack of strong positive catalysts and the ongoing financial challenges lead to a negative sentiment, predicting a stock price decrease of -2% to -8%.
Affimed N.V. (AFMD) Q2 2024 Earnings Call Summary
Negative
2024-09-05
The earnings call reveals several negative aspects: declining revenue, significant cash burn, and lack of shareholder return plans. Operational and regulatory risks are highlighted, along with competitive pressures. Although there is optimism in clinical programs, management's vague responses in the Q&A section and the absence of new partnerships or positive guidance adjustments contribute to a negative outlook. The stock price is likely to fall between -2% to -8% due to these factors.
People Also Watch
IZM
ICZOOM Group Inc
2.560
USD
0.00%
FEBO
Fenbo Holdings Ltd
0.731
USD
-2.53%
PLAG
Planet Green Holdings Corp
1.850
USD
+0.54%
NCL
Northann Corp
0.158
USD
+0.64%
SOHO
Sotherly Hotels Inc
0.821
USD
+2.62%
CLIK
Click Holdings Limited
0.349
USD
+8.39%
LFWD
Lifeward Ltd
0.717
USD
+1.56%
SAIH
SAIHEAT Ltd
7.685
USD
+1.49%
GIGM
GigaMedia Ltd
1.520
USD
0.00%
CRVO
CervoMed Inc
9.640
USD
+2.55%
FAQ
What were the key highlights of AFMD’s latest earnings report for FY2024Q2?
AFMD reported its FY2024Q2 earnings on 2024-09-05, showcasing a revenue of 154.00K against an estimate of 1.15M, resulting in a -86.65% surprise. The EPS was -1.09, surpassing the expected -1 by -9% . The stock experienced a 1.07% price change on the earnings day and a 2.67% change over the next five days, reflecting market reactions to the results.
How did AFMD’s stock price react after the FY2024Q2 earnings release?
What are the revenue and EPS estimates for AFMD for 2024/Q4?
How does AFMD’s stock price correlate with earnings forecast revisions?
What should investors expect from AFMD’s next earnings report?